Fig. 3

High AURKA expression associates with poor survival. A High Aurora-A expression associates with shorter disease-specific survival (n = 291; in-house cohort). B–C High AURKA mRNA expression associates with shorter disease-specific survival in METABRIC validation- (B; n = 843) and discovery cohort (C; n = 939) cohort. (D) Recurrence-free breast cancer survival according to AURKA mRNA in the cohorts from the online KM plotter database (n = 4929; www.kmplot.com). E–F When adjusting for traditional prognostic variables, AURKA mRNA demonstrated independent association with shorter disease-specific survival (E; Cox multivariate analysis) also when adding molecular subtypes to the analysis (F). The lines represent a hazard ratio (HR) of 1.0, and error bars represent 95% CI. G–H High AURKA expression was also significantly associated with shorter survival in luminal A tumors (METABRIC discovery and KM plotter cohorts, n = 466 and n = 2277 respectively). KM plots: numbers in brackets indicate number of patients/number of events